Skip to main content

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


July 19th Options Now Available For ADMA Biologics

2024-05-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Zacks.com featured highlights ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education

2024-05-16
ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education have been highlighted in this Screen of The Week article.

5 Stocks With Recent Price Strength to Tap May's Rally

2024-05-15
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, NTIC, AGS, MBIN, STRA.

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

2024-05-13
Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.

Biotech Alert: Searches spiking for these stocks today

2024-05-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS

2024-05-13
OAKLAND, Calif., May 13, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of California has approved the following...

Giving ADMA Biologics A Well-Deserved 'Booyah'

2024-05-12
ADMA Biologics is executing quite well and is situated in a large and growing market. Click here to see why ADMA stock is a Hold.

ADMA Biologics First Quarter 2024 Earnings: Beats Expectations

2024-05-11
ADMA Biologics ( NASDAQ:ADMA ) First Quarter 2024 Results Key Financial Results Revenue: US$81.9m (up 44% from 1Q...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call Transcript

2024-05-10
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call Transcript May 9, 2024 ADMA Biologics, Inc. beats earnings expectations. Reported EPS is $0.07532, expectations were $0.05. ADMA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the […]

ADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024

2024-05-10
Robust Growth and Upward Financial Guidance Highlight a Strong Quarter